Despite early diagnosis through newborn Bloodspot Screening and strict dietary treatment, there are long-term complications of Classical Galactosaemia, including female infertility, osteopenia, and, in some cases, learning disabilities or neurological symptoms such as tremor or ataxia. Therefore, neurological symptoms may easily be attributed to an underlying diagnosis of Classical Galactosaemia. However, the coexistence of classical Galactosaemia and Friedreich’s Ataxia (FRDA) was previously reported amongst the Irish Traveller population. Classical Galactosaemia and FRDA are both autosomal recessive conditions, the gene loci for which are located on either side of the centromere of chromosome 9. FRDA is one of the most common forms of autosomal-recessive ataxia and slowly progressive; it also commonly involves the heart. We here present the clinical spectrum of 10 Irish patients currently being treated in our Metabolic Centre in whom a diagnosis of Classical Galactosaemia together with FRDA was made. All patients were diagnosed with Classical Galactosaemia through newborn Screening first. All were diagnosed with the common Classical Galactosaemia GALT mutation Q188R/Q188R. Eight of the ten patients later presented with progressive ataxia, between the ages of 7–14 years. One child presented in cardiac failure secondary to dilated cardiomyopathy at 7 years of age. It was noted that he was not ataxic at presentation of FRDA and that he had normal tendon reflexes. Another patient who was diagnosed at 6 years of age still had an essentially normal neurological exam almost 4 years later. The diagnosis of FRDA was confirmed by detecting the common pathogenic GAA repeat expansion mutations in both alleles of the frataxin gene (FXN) in affected individuals.

Taken together, neurological signs may easily be attributed to an established diagnosis of Classical Galactosaemia. However, one should be vigilant for the coexistence of Classical Galactosaemia and FRDA in a high-risk population, particularly when monitoring patients with a complex phenotype, such as a neurological or cardiac presentation.

**Objective** To examine the neuropsychological profile of children at perinatal risk with or without CP, compare them to each other and to the normative group. It is expected that more specific cognitive deficits will be found in both clinical groups in relation to the normative group, as well as more deficits in children with CP compared to children at perinatal risk without CP.

**Design/study groups** Clinical sample of 46 children with milder CP (the CP group) and 55 children at perinatal risk without CP (the group at risk) in the age range between 5 and 12 years with normal verbal intelligence (according to WISC-III) were examined. The groups are equalized in terms of demographic variables (child’s age and sex; mother’s education) as well as in terms of perinatal variables (gestational age, birth weight, Apgar scores, presence of brain lesion – 78% in each group), and EEG findings at the time of examination.

**Main outcome measures** Developmental Neuropsychological Assessment (NEPSY) has been applied to measure neuropsychological functions, all the core subtests except Phonological Processing.

**Results** Both clinical groups had significantly lower results in 12 out of 13 measures applied in relation to the normative group; in Auditory and Visual Attention, Speeded Naming, Comprehension of Instructions, Fingertip Tapping, Imitation Hand Positions, Visuomotor Precision, Design Copy, Arrows, Memory for Faces, Memory for Names and Narrative Memory (z-score = -.29 to -1.67 in the CP group and z-score = -0.38 to -1.07 in the group at risk). The CP group had lower results in comparison to the group at risk in 5 measures which include a motor component (oral or manual) in performance. The group at risk had worse results in the Memory for Names than the CP group.

**Conclusion** The children at perinatal risk achieved significantly lower neuropsychological results in comparison to the normative group, regardless of motor deficit (in the most of measures) or any demographic and perinatal variable or EEG findings. It may be concluded that both clinical groups are at risk for specific cognitive deficits. That has significant implications for neuropsychological examination and treatment, where the model of developmental neuropsychological psychotherapy may be applied.

**Background** Glycogen Storage Disease (GSD) Type IIIa is a recessively inherited disorder caused by a deficiency in the debranching enzyme amylo-1,6-glucosidase. This deficiency allows for the accumulation of glycogen in the liver, heart and skeletal muscle. Typically patients present in infancy with recurrent hypoglycaemia and hepatomegaly. Standard treatment is a high carbohydrate, moderate to high protein and low fat diet, with regular feeds to help maintain euglycaemia. Conversely the ketogenic diet (KD) consists of a very high fat, low carbohydrate diet with moderate protein intake and has traditionally been used for treatment of epilepsy. It has well noted that ketone bodies can be used as an alternative energy source when carbohydrate intake is low to maintain euglycaemia.
Patient was a 3-year-old male who had neonatal hypoglycaemia and confirmed homozygosity for the GSD Type IIIa gene. Patient was commenced on the KD at 8 months of age when progression of his GSD resulted in severe cardiomyopathy. The following outlines the transition onto the KD and clinical findings between 8-22 months.

**Method** Standard dietetic treatment was provided from birth to maintain euglycaemia along with placement of a percutaneous endoscopic gastrostomy. Continuous 24-hour feeding was required due to unsuccessful bolus feeding. A modified KD incorporating MCT fat—which was found to be further aid ketosis—was commenced at 8 months with a ketogenic ratio of 0.5:1 building to 1:1 within 2 weeks. Ketones and blood sugar levels were closely monitored with a threshold of 2.6 mmol/L of glucose and ketones >1 mmol/L before hypoglycaemia intervention was required.

**Results** Prior to the KD, there was a high glucose infusion rate (GIR) of 9.75 mg glucose/kg/minute. After initiation of the KD, the GIR reduced initially to 5.8 mg glucose/kg/minute, with a gradual increase of MCT fat from 6% to 28% and the GIR further reduced to 2.73 mg glucose/kg/minute. There were no episodes of hypoglycaemia and ketones ranged from 1–2.9 mmol/L. Echocardiographs showed a significant improvement in cardiac function with a cardiac output reduction of 137 to 39 mmHg.

**Discussion** The KD was trialled as an alternative treatment. It resulted in the reduced intake of carbohydrate and the subsequent reduction of glycogen build-up within cardiac muscle. Ketones were used as an alternative fuel source and euglycaemia was maintained.

**Conclusion** The KD should be considered as an alternative treatment for GSD Type IIIa where standard intervention is not effective.